AstraZeneca’s Tezepelumab found to significantly reduce Asthma Exacerbations
One of the global Biopharma Majors, AstraZeneca has recently announced that their Biologics License Application (BLA) for Tezepelumab has been granted Priority Review by the US FDA. This acceptance of Priority Review is for the treatment of Asthma. As per the company’s recent press release, Tezepelumab which is developed in collaboration with Amgen is the…
News ViewsPatent Waiver for Vaccines and how does it impact access to COVID-19 Vaccines?
The proposed Patent or IP waiver for the COVID-19 Vaccines appears to be a closer reality now. The Biden Administration in the US is convinced that waiving off the IP restrictions for Coronavirus vaccines is a fair thing to do. The European Union may also incline to this narrative which is to be confirmed in…